Increased levels of exhaled sICAM1, sVCAM1, and sE-selectin in patients with non-small cell lung cancer  by Zhou, Feng et al.
Respiratory Medicine (2014) 108, 1670e1676Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate /rmedIncreased levels of exhaled sICAM1, sVCAM1,
and sE-selectin in patients with non-small
cell lung cancer
Feng Zhou a, Jianrong Chen b, Guohua Tao a, Mingxun Zhu b,
Wei Xie a, Xingjian Cao a,*a Department of Clinical Laboratory, Second Affiliated Hospital of Nantong University, Nantong,
Jiangsu, China
b Department of Respiratory Medicine, Second Affiliated Hospital of Nantong University, Nantong,
Jiangsu, ChinaReceived 5 March 2014; accepted 12 August 2014
Available online 20 August 2014KEYWORDS
Exhaled breath
condensate;
Non-small cell lung
cancer;
Soluble E-selectin;
Soluble intercellular
adhesion molecule 1;
Soluble vascular cell
adhesion molecule 1Abbreviations: COPD, chronic obstruc
NSCLC, non-small cell lung cancer; sIC
VCAM1, vascular cell adhesion molecu
* Corresponding author. Department
China. Tel.: þ86 513 85061082.
E-mail address: ntcaoxh@163.com
http://dx.doi.org/10.1016/j.rmed.20
0954-6111/ª 2014 Elsevier Ltd. All rigSummary
Aim: The mortality of lung cancer remains high and methods for early diagnosis are still lack-
ing. Recently, exhaled breath condensate (EBC) has been considered a potential tool for ob-
taining biological information leading to a reliable diagnosis of non-small cell lung cancer
(NSCLC).
Objective: This study assessed the potentials of exhaled and serum concentrations of solu-
ble(s) forms of intercellular adhesion molecule 1 (sICAM1), vascular cell adhesion molecule 1
(sVCAM1), and E-selectin as biomarkers for diagnosis and predicting metastasis in NSCLC pa-
tients.
Methods: We enrolled 33 patients with NSCLC, 35 patients with chronic obstructive pulmonary
disease (COPD) and 30 healthy controls. EBC and serum samples from subjects were collected
at the time of diagnosis and, where applicable, 3 months after surgical treatment. Measure-
ments of sICAM1, sVCAM1, and sE-selectin were determined by enzyme immunoassay.
Results: Concentrations of sICAM1, sVCAM1, and sE-selectin in the EBC and sera of NSCLC pa-
tients were significantly elevated compared to COPD patients and healthy controls. The
exhaled and serum levels of sICAM1 and sVCAM1, but not sE-selectin, decreased significantly
after tumor resection from pre-surgery levels. In addition, analyzed results showed a correla-
tion between exhaled sICAM1 levels and disease progression of NSCLC patients.tive pulmonary disease; EBC, exhaled breath condensate; ICAM1, intercellular adhesion molecule 1;
AM1, soluble intercellular adhesion molecule 1; sVCAM1, soluble vascular cell adhesion molecule 1;
le 1.
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Induced exhaled adhesion molecules in patients with NSCLC 1671Conclusions: Our results suggest that the levels of sICAM1, sVCAM1, and sE-selectin in EBC and
sera of NSCLC patients are higher than those of COPD patients or healthy controls. Moreover,
exhaled sICAM1 may have prognostic value and potential as a biomarker for the diagnosis and
prognosis of patients with lung cancer.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Lung cancer still remains the most frequent cause of
cancer-related death. Survival rates are poor despite sub-
stantial improvements in diagnosis and treatment [1,2].
Early diagnosis of this malignancy is a major challenge, as
symptoms occur predominantly in the later stages [3,4]. To
date, surgery is the only curative option, and adequate
tumor extirpation can only be performed at its early stage.
Thus, the development of effective screening methods for
early diagnosis and prognosis has great clinical importance.
Recently, exhaled breath condensate (EBC), obtained by
cooling exhaled air under spontaneous breathing condi-
tions, has been proposed to monitor lung pathobiology.
Various biomarkers in EBC have been identified and evalu-
ated in inflammation and oxidative stress [5] and [6]. Many
researchers have applied this technology to screen cancer
biomarkers [7,8]. Moreover, nanomaterial-based sensors
have been successfully developed to identify diagnostic and
prognostic biomarkers in disease-related EBC [9,10].
Intercellular adhesion molecule 1 (ICAM1) and vascular
cell adhesion molecule 1 (VCAM1) are members of the
immunoglobulin superfamily that have an important role in
enabling the adhesion of host cells to cancer cells [11]. In
normal lung tissue, ICAM1 is expressed mainly by bronchial
and alveolar epithelial cells [12]. However, ICAM1 was
shown to enhance the metastatic ability of malignant tu-
mors [13] and is strongly expressed in all histological types
of NSCLC [14]. In addition, high concentrations of the sol-
uble form of ICAM1 (sICAM1) in the circulation have been
reported in several malignant diseases, including lung
cancer [15,16], and thus sICAM1 may be a reliable surrogate
marker for predicting the efficacy of chemotherapy and
prognosis in cancer patients.
VCAM1 is found in endothelial cells, dendritic cells,
macrophages, renal parietal epithelial cells, synovial lining
cells and reactive mesothelial cells [17]. Soluble forms of
VCAM (sVCAM) have been identified, and elevated serum
levels of sVCAM have been reported in a variety of malignant
tumors [11,18e20]. Moreover, ICAM1 and VCAM1 signaling
pathways are involved in the activation of GTPases, pro-
duction of reactive oxygen species, and phosphorylation of
target proteins, which cause junctional disruption, cyto-
skeletal remodeling, and/or membrane fusion events [21].
E-selectin (also known as endothelial leukocyte adhesion
molecule 1) is a transmembrane protein containing lectin-
like and endothelial growth factor-like domains, followed
by short cysteine-rich repeats. E-selectin is absent from
normal skin, but is strongly expressed by dermal endothe-
lium in both squamous cell and basal cell carcinomas
[22,23]. Also, it is released in a soluble form (i.e., sE-selectin) by endothelial cells and is easily detected in
sera [11,24,25].
At present, no study has documented the levels of
sICAM1, sVCAM1, or sE-selectin in the EBC of patients with
lung cancer. This study assessed whether these molecules
in EBC and sera of NSCLC patients could have diagnostic and
prognostic value.
Materials and methods
Characteristics of the patients
The study population consisted of 98 subjects: (a) 30 healthy
individuals (controls); (b) 35 patients with chronic obstruc-
tive pulmonary disease (COPD); (c) 33 patients with NSCLC.
Subjects were consecutively enrolled at the Department
of Thoracic Surgery and Department of Respiratory Medi-
cine in our Hospital. Written informed consent was ob-
tained from all subjects upon approval of the study by the
Ethical Committee at the Second Affiliated Hospital of
Nantong University. All the patients were enrolled in the
study before pathological diagnosis and a complete physical
examination (including lung X-ray) was performed,
including neurologic; cardiopulmonary; and ear, nose, and
throat examinations prior to treatments (surgery, radiation
or chemotherapy). Alcohol assumption was prohibited for
all subjects for 24 h before the procedure.
Following cytohistological diagnosis, patients with
NSCLC underwent clinical examination, plain chest X-ray, a
computed tomography (CT) scan of the chest, upper
abdomen and brain, fiberoptic bronchoscopy, and bone
scan. The diagnosis of NSCLC was confirmed either by
bronchoscopic biopsy or by transthoracic needle aspiration.
EBC and sera collection
EBC and serum samples from NSCLC patients were collected
at the time of diagnosis and 3 months after surgical treat-
ment. Samples from COPD patients and healthy controls
were collected at the time of diagnosis. Briefly, EBC was
collected between 8 am and 10 am. Before collection, all
subjects were required to do fast overnight, and refrain
from smoking or drinking for 24 h. EBC was collected using a
condenser (EcoScreen, Germany), which allowed for the
noninvasive collection of non-gaseous components of the
exhaled air. While wearing a nose clip patients and control
subjects breathed through a mouthpiece and a two-way
non-rebreathing valve (which also served as a saliva trap) at
a normal frequency and tidal volume for a period of 10 min.
If they felt saliva in their mouth, they were instructed to
Table 1 Demographic data of the NCSLC, COPD, and healthy controls.
NSCLC COPD Healthy
Number of subjects 33 35 30
Age (mean  SD) 61.2  8.5 60.2  9.1 59.1  7.6
Gender, male/female 25/8 26/9 22/8
Smoker/non-smoker 10/23 10/25 9/21
Histology Adenocarcinoma 13 e e
Squamous cell carcinoma 17 e e
Large cell carcinoma 3 e e
Tumor stage I 2 e e
II 7 e e
III 8 e e
IV 16 e e
The age was analyzed by t-test, while the gender or smoking was analyzed by chi-squared test.
1672 F. Zhou et al.swallow it. The condensate, at least 1 mL, was collected on
ice at 20 C into 1.5 mL microcentrifuge tubes and
immediately stored at 80 C for subsequent analysis.
Peripheral blood samples were collected into sterile
glass tubes in the morning after an overnight fast. The
samples were allowed to coagulate at room temperature
for 30 min and then were centrifuged at 2500 g for 20 min.
The serum was separated and stored at 70 C until
analyzed. Before analysis, EBC and serum samples were
thawed slowly and mixed gently.
Measurement of sICAM1, sVCAM1 and sE-selectin
levels
Quantitative sandwich enzyme immunoassay kits (R&D
systems, UK) were used to measure the concentrations of
sICAM1, sVCAM, and sE-selectin in the EBC and sera. Results
are reported as mean  standard deviation (SD). The
sensitivity levels of the tests for sICAM1, sVCAM, and sE-
selectin were 0.25 ng/mL, 1.25 ng/mL, and 0.025 ng/mL,
respectively. The intra- and inter-assay coefficients of
variation for each were 7%, 8%, and 9%.Statistical analysis
Results were statistically analyzed using the t-test and
analysis of variance test. This was followed by the Wilcoxon
signed-rank test. Statistical analyses were performed usingTable 2 EBC levels of soluble adhesion molecules in NSCLC pat
NSCLC
Before resection After re
sICAM1 63.4  26.0d,e,f 44.0  1
sVCAM1 52.1  21.5d,e,f 37.7  1
sE-selectin 6.96  2.79d,e 5.87  2
a n Z 33.
b n Z 35.
c n Z 30.
d p < 0.001, compared with COPD patients.
e p < 0.001, compared with the healthy controls.
f p < 0.01, compared with NSCLC patients after tumor resection.SPSS version 17.0 (SPSS, Chicago, IL, USA). A p-value <0.05
was considered significant.
Results
Subjects’ characteristics
There were no significant differences in terms of age,
gender, or smoking status among the NSCLC, COPD, and
healthy control groups (Table 1). Staging in the NSCLC group
revealed that 48.5% of the patients (16/33) had distant me-
tastases. Thus, we divided the NSCLC patients into two
groups: the first group (17/33) included patients without
distant metastasis (stage I-III), whereas the second group
included patients with distant metastasis, pleural dissemi-
nation, ormetastasis to the contralateral lung (stage IV) [26].
Concentrations of soluble adhesion molecules in
EBC and sera
In NSCLC patients, the concentrations of sICAM1, sVCAM1,
and sE-selectin in both EBC and sera were significantly
higher than in either the COPD or the healthy controls
(p < 0.001 for all comparisons, Table 2 and Table 3).
In NSCLC patients, the concentration of sICAM1 in EBC
was 63.4  26.0 ng/mL (range: 23.3e120.2 ng/mL) and in
sera 660  271 ng/mL (232e1268 ng/mL). In the COPD
patients the sICAM1 in EBC was 39.5  16.9 ng/mLientsa, COPD patientsb, and healthy individualsc, ng/mL.
COPD Healthy
section
7.7 39.5  16.9e 16.4  4.6
4.0 33.7  13.9 29.7  10.9
.06 3.77  1.48 3.67  1.39
Table 3 Serum levels of soluble adhesion molecules in NSCLC patientsa, COPD patientsb, and healthy individualsc, ng/mL.
NSCLC COPD Healthy
Before resection After resection
sICAM1 660  271d,e,f 454  194 388  162e 172  57
sVCAM1 733  311d,e,f 583  218 404  180 324  117
sE-selectin 74.0  30.8d,e 66.0  27.1 40.8  15.2 38.2  14.2
a n Z 33.
b n Z 35.
c n Z 30.
d p < 0.001, compared with the COPD patients.
e p < 0.001, compared with the healthy controls.
f p < 0.01, compared with NSCLC patients after tumor resection.
Figure 1 The correlation between EBC levels of soluble
adhesion molecules and distant metastasis in patients with
NSCLC. EBC samples from metastasis and no metastasis NSCLC
patients were collected upon diagnosis. sICAM1, sVCAM1 and
sE-selectin concentrations were measured using quantitative
sandwich enzyme immunoassay. The correlation between EBC
levels of soluble adhesion molecules and distant metastasis in
patients with NSCLC were determined using KruskaleWallis
analysis of variance (ANOVA). *A significant difference
compared to the no metastasis group (p < 0.01). &A significant
difference compared to the control group (p < 0.001). #A sig-
nificant difference between no metastasis and controls
(p < 0.01).
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(152e801 ng/mL). In the healthy controls, the sICAM1 in
EBC was 16.4  4.6 ng/mL (7.3e25.2 ng/mL), and in sera it
was 172  57 ng/mL (79.8e291 ng/mL).
The sVCAM1 concentration in the EBC of NSCLC patients
was 52.1  21.5 ng/mL (range 21.7e106.7 ng/mL), and that
of sera was 733  311 ng/mL (298e1435 ng/mL). In the
COPD patients, sVCAM1 in the EBC was 33.7  13.9 ng/mL
(17.2e64.1 ng/mL), and was 404  180 ng/mL
(194e803 ng/mL) in sera. For the healthy controls, the
sVCAM1 in the EBC was 29.7  10.9 ng/mL (14.6e51.8 ng/
Ml), and was 324  117 ng/mL (174e583 ng/mL) in sera.
The sE-selectin concentration in the EBC of NSCLC patients
was 6.96 2.79ng/mL (range: 2.95e13.20ng/mL), and in sera
the sE-selectin was 74.0  30.8 ng/mL (30.4e148 ng/mL). In
the COPD patients, sE-selectin in the EBC was 3.77 1.48 ng/
mL (1.89e6.85 ng/mL), and in sera 40.8  15.2 ng/mL
(19.4e71.0 ng/mL). In the healthy controls the sE-selectin in
the EBC was 3.67  1.39 ng/mL (1.82e6.49 ng/mL), and
38.2  14.2 ng/mL (18.9e66.7 ng/mL) in sera.
Correlation between concentrations of soluble
adhesion molecules and distant metastasis
We found that the concentrations of sICAM1 in the EBC were
strongly correlated with distant metastasis in the NSCLC
patients (Fig. 1). In NSCLC patients with metastatic disease,
the mean concentration of sICAM1 (76.6  22.5 ng/mL) was
significantly higher (p < 0.01) than that of NSCLC patients
with no metastasis (51.0  23.3 ng/mL; Fig. 1). However,
there was no correlation between concentrations of either
sVCAM1 or sE-selectin and the presence of distantmetastasis
in the NSCLC groups (Fig. 1). There were also no such cor-
relations observed between the serum concentrations of
sICAM1, sVCAM1, or sE-selectin and distant metastasis in the
NSCLC groups (Fig. 2). Interestingly, we also observed that
the sICAM1 level in the EBC was significantly higher in the
NSCLC patients with lymph nodemetastasis and at late stage
(IV) (Table 4), while the serum sICAM1 level was not associ-
ated with any clinical characteristics analyzed (Table 5).
Effects of tumor resection on the levels of soluble
adhesion molecules in NSCLC patients
To study the effect of tumor resection on the levels of
soluble adhesion molecules in all NSCLC patients (i.e., withor without metastasis), we measured and compared the
concentrations of sICAM1, sVCAM1, and sE-selectin in the
same patients before and 3 months after surgery.
In EBC, the levels of sICAM1 and sVCAM1, but not sE-
selectin, decreased significantly after radical resection of
the tumor compared to preoperative levels (p < 0.01, all).
The pre- and post-surgery concentrations of sICAM1 were
63.4  26.0 ng/mL and 44.0  17.7 ng/mL, respectively;
and those of sVCAM1 were 52.1  21.5 and 37.7  14.0 ng/
mL (Table 2).
Similarly, in sera the levels of sICAM1 and sVCAM1, but
not sE-selectin, decreased significantly after surgery
(p < 0.01, all). The pre- and postoperative serum levels of
Figure 2 The correlation between serum levels of soluble
adhesion molecules and distant metastasis in patients with
NSCLC. Serum samples in the metastasis, the no metastasis and
the control groups were collected at the time of diagnosis.
sICAM1, sVCAM1 and sE-selectin concentrations were measured
using quantitative sandwich enzyme immunoassay kits (R&D
systems, UK). The correlation between serum levels of soluble
adhesion molecules and distant metastasis in patients with
NSCLC were determined using KruskaleWallis analysis of vari-
ance (ANOVA). #Indicates significant difference as compared to
the control group (p < 0.001). &Indicates significant difference
between the metastasis and the controls (p < 0.001).
1674 F. Zhou et al.sICAM1 were 660  271 ng/mL and 454  194 ng/mL,
respectively, and those of sVCAM1 were 733  311 and
583  218 ng/mL (Table 2).Discussion
Our data showed that sICAM1, sVCAM1, and sE-selectin
were detected in the EBC and sera of all subjects, butTable 4 Association between EBC levels of soluble adhesion m
n sICAM1
ng/mL
Gender Male 25 65.4  2
Female 8 57.3  1
Smoking history Smoker 10 68.5  2
Non-smoker 23 61.1  2
Tumor size 3 cm 17 57.9  1
>3 cm 16 69.4  2
Histology Adenocarcinoma 13 64.3  2
Squamous carcinoma 17 61.7  1
Large cell carcinoma 3 69.0  2
Lymph node metastasis Positive 10 79.8  2
Negative 23 56.1  2
Tumor stage I þ II þ III 17 51.0  2
IV 16 76.6  2significantly higher levels of sICAM1, sVCAM1, and sE-
selectin were observed in the NSCLC patients compared
to either COPD patients or healthy individuals. These re-
sults are consistent with previous studies [25,27]. These
findings suggest that levels of sICAM1, sVCAM1, and sE-
selectin may be used as diagnostic markers for lung can-
cer. Furthermore, the exhaled concentrations of sICAM1
were significantly higher in NSCLC patients with metastatic
disease compared to those NSCLC patients without metas-
tasis. This implies that sICAM1 in EBC can be used as a
predictor of progression in NSCLC.
High expression of ICAM1 NSCLC indicates that ICAM1
plays a role in the inflammation and tumor growth induced
by immune responses. Moreover, an in vitro study showed
that the adherence of SCLC cell lines to cultured vascular
endothelium is dependent on ICAM1 expression, suggesting
a very important role of sICAM1 in the metastatic process
[28]. In the present study, we found that the concentration
of sICAM1 in EBC positively correlated with distant metas-
tasis in NSCLC patients. This provides further evidence that
sICAM1 may be involved in the development and progres-
sion of NSCLC [27,29].
It has been demonstrated that exhaled sVCAM1 has a role
in cancer development. Mukae and colleagues [30] reported
that VCAM1might play a role in the generation of an effective
pulmonary immune response. This is the first study to report
elevated sVCAM1 levels in EBC from NSCLC patients. In lung
cancer, VCAM1 on the surface of cancer cells binds to a4b1
integrin on metastasis-associated macrophages, and thus
triggers VCAM1-mediated activation of phosphoinositide 3-
kinase growth and the survival pathway in the cancer cells
[31]. sVCAM1 levels in EBC may have diagnostic, predictive,
and prognostic value in NSCLC patients. A previous study
showed that VCAM1 promoted pulmonary metastasis in a
mousemodel [32], but the role of VCAM1 in themetastasis of
NSCLC has been rarely reported. In the present study, we
found that concentrations of both exhaled and serum
sVCAM1 was not associated significantly with distant
metastasis of NSCLC. Moreover, the EBC and serum levels of
sICAM1 and sVCAM1 significantly decreased after radical
resection in NSCLC patients. One study reported that
elevated sVCAM1 serum levels in patients with metastaticolecules and NSCLC patient clinical characteristics.
sVCAM1 sE-selectin
p ng/mL p ng/mL p
5.1 0.404 53.1  23.0 0.619 6.81  0.29 0.517
8.6 48.7  17.0 7.41  0.20
7.5 0.413 54.1  29.1 0.732 7.38  0.27 0.655
1.4 51.2  18.1 6.77  0.23
9.6 0.298 48.7  19.8 0.312 7.24  0.29 0.412
3.6 55.5  23.8 6.67  0.18
6.3 0.772 48.9  25.8 0.695 7.21  0.26 0.732
9.7 55.9  18.3 6.83  0.19
9.5 53.3  27.4 6.67  0.30
6.3 0.036 60.1  24.4 0.162 7.89  0.27 0.226
4.1 48.6  19.7 6.55  0.20
3.3 0.003 45.7  17.9 0.079 6.17  0.22 0.103
2.5 58.9  23.5 7.81  0.28
Table 5 Association between the serum levels of soluble adhesion molecules and NSCLC patient clinical characteristics.
n sICAM1 sVCAM1 sE-selectin
ng/mL P ng/mL P ng/mL P
Gender Male 25 679  267 0.379 751  267 0.417 73.1  30.3 0.727
Female 8 602  306 678  328 76.8
Smoking history Smoker 10 687  283 0.712 744  294 0.809 76.8  32.8 0.633
Non-smoker 23 649  237 728  301 72.7  29.6
Tumor size 3 cm 17 681  227 0.601 785  321 0.218 77.6  31.7 0.341
>3 cm 16 636  25.8 679  287 70.1  28.5
Histology Adenocarcinoma 13 644  238 0.804 757  295 0.721 78.6  28.3 0.605
Squamouscarcinoma 17 677  264 710  278 71.6  29.4
Large cell carcinoma 3 628  305 764  331 67.4  33.7
Lymph node metastasis Positive 10 723  294 0.285 791  302 0.377 81.6  31.7 0.218
Negative 23 634  245 709  307 70.8  28.8
Tumor stage I + II + III 17 609  279 0.194 704  340 0.508 69.2  32.8 0.234
IV 16 715  267 765  289 79.1  29.2
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with unfavorable outcome [33]. These data indicate that the
levels of sICAM1 and sVCAM1 in EBC and serum can be used as
prognostic markers for NSCLC patients. Interestingly, higher
levels of sICAM1 and sVCAM1 were also observed in the EBC
from asthmatic children, relative to controls [34,35], sug-
gesting that ICAM1 and VCAM1 are likely involved in the
development of asthma in childhood. Because both sICAM1
and sVCAM1 were elevated in NSCLC and asthma patients, it
is necessary to use other biomarkers to differentiate NSCLC
from asthma. Izbicka et al. [36] found that EGF and IL-8 were
strong predictors of NSCLC but not asthma, which may
improve the diagnosis of NSCLC.
Previous studies have shown that levels of sE-selectin
are increased in benign lung disease and lung cancer
[37,38]. Here we observed that the exhaled concentrations
of sE-selectin were significantly higher in NSCLC patients.
Moreover, the upregulation of E-selectin in lung cancer,
compared with the limited expression in normal body tis-
sues, makes it a potential target for therapeutic purposes.
Roselli et al. [37] observed that elevated concentrations of
sE-selectin were related to the presence of distant metas-
tasis in patients with squamous lung cancer. However, we
did not find a correlation between sE-selectin and the
presence of distant metastasis in our patients with NSCLC.
Different subtypes of lung cancer may have different
pathophysiology, but the discrepancy in the role of sE-
selectin in metastasis needs further investigation.
The patients in this study were not followed up pro-
spectively, which prevented us from determining if sICAM1,
sVCAM1, or sE-selectin are biomarkers for recurrence and
overall survival in NSCLC. Nevertheless, this report could
serve as a pilot study for exploring the roles of exhaled
sICAM1, sVCAM1, or sE-selectin in the early diagnosis of
suspected lung cancer when bronchoscope and other
established diagnostic results are negative. In addition, this
study serves as a firm rationale for further research with a
larger population to determine the differences among TNM
stages in the levels of sICAM1, sVCAM1, or sE-selectin in EBC
and serum.
In summary, we found that the levels of sICAM1, sVCAM,
and sE-selectin were significantly elevated in the EBCs andsera from patients with NSCLC, and serum levels of sICAM1
and sVCAM1, but not sE-selectin, significantly decreased
after radical resection. More importantly, exhaled sICAM1
levels were associated with distant metastasis in NSCLC
patients. These data suggest that levels of sICAM1, sVCAM,
and sE-selectin can be used as potential biomarkers for the
diagnosis or prognosis of patients with NSCLC.Conflict of interests
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